KHẢO SÁT TÍNH HIỆU QUẢ VÀ AN TOÀN CỦA THUỐC REMDESIVIR TRONG ĐIỀU TRỊ BỆNH NHÂN COVID-19 TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI

Abstract

Introduction: This study was aimed to evaluate the efficacy and safety of remdesivir in COVID-19 patients at Hospital for Tropical Diseases. Methods: A retrospective study was conducted with 1734 medical records of COVID-19 patients with confirmed diagnosis between July 7th, 2021 and September 15th, 2021, including 182 patients who received at least one dose of remdesivir (remdesivir group) between August 16th, 2021 and September 15th, 2021. Results: The median age of 1734 patients enrolled in the study was 54; nearly 90% of patients were admitted with mild/moderate conditions. There were significant differences in age (p<0,001), BMI (p<0,001), comorbid diabetes (p=0,007), oxygenation and ventilation (p=0,002) between the remdesivir and the non-remdesivir group. Among patients in the remdesivir group, the mortality rate 22,5 was recorded; the most commonly reported adverse events comprised hypokalemia (75,3%), elevated liver enzymes (55,5%), and decreased glomerular filtration rate (21,4%). The remdesivir group did not improve mortality compared with the non-remdesivir group (HR 1.30; 95% CI: 0.92 – 1.84). Factors associated with increased mortality (HR>1; p<0.05) comprised increasing age, comorbid diabetes, increased ASL/ALT, severe clinical status by Ministry of Health, evidence of infection. Factors associated with decreased mortality (HR<1; p<0.05) comprised normal creatinin clearance, and anticoagulation use. Conclusion: There was no statistically significant difference in mortality rate between the remdesivir group and the non-remdesivir group. The most common adverse events during treatment included elevated liver enzymes, decreased glomerular filtration rate, and hypokalemia.